Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
BJU International
|
January 31, 2024
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
Axel Gerdtsson, Helene F S Negaard, Bjarte Almås, et al.
European Urology Oncology
|
March 22, 2021
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
Axel Gerdtsson, Anna Thor, Anna Grenabo Bergdahl, et al.
BJU International
|
May 2, 2023
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
Axel Gerdtsson, Gustav Torisson, Anna Thor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma
Stefanie Fischer, Torgrim Tandstad, Matthew Wheater, et al.
BJU International
|
March 12, 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Sven Löffeler, Helena Bertilsson, Christoph Müller, et al.
European Urology Open Science
|
July 5, 2024
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
Anna Thor, Helene F S Negaard, Anna Grenabo Bergdahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Stefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Torgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer
Luca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
Silke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
BJU International
|
January 31, 2024
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
Axel Gerdtsson, Helene F S Negaard, Bjarte Almås, et al.
European Urology Oncology
|
March 22, 2021
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
Axel Gerdtsson, Anna Thor, Anna Grenabo Bergdahl, et al.
BJU International
|
May 2, 2023
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
Axel Gerdtsson, Gustav Torisson, Anna Thor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma
Stefanie Fischer, Torgrim Tandstad, Matthew Wheater, et al.
BJU International
|
March 12, 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Sven Löffeler, Helena Bertilsson, Christoph Müller, et al.
European Urology Open Science
|
July 5, 2024
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
Anna Thor, Helene F S Negaard, Anna Grenabo Bergdahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Stefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Torgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer
Luca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2021
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
Silke Gillessen, Nicolas Sauvé, Laurence Collette, et al.
Page
of 7